Epigenomics AG
Holding company investing in blood-based tests for early cancer detection.
ECX | F
Overview
Corporate Details
- ISIN(s):
- DE000A37FT41 (+2 more)
- LEI:
- 549300X1C4U862NDLN97
- Country:
- Germany
- Address:
- Bertha-Benz-Str. 5, 10557 Berlin
- Website:
- https://www.epigenomics.com/
Description
Epigenomics AG operates as a holding company dedicated to managing its assets and investments. The company's primary investment focus is on the field of molecular diagnostics, particularly in companies developing minimally invasive, blood-based tests for the early detection of cancer. This strategy leverages the company's historical expertise in the development of in vitro diagnostic products based on DNA methylation biomarkers.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-05-02 00:00 |
Jahresabschluss zum Geschäftsjahr vom 01.01.2024 bis zum 31.12.2024
|
German | 449.8 KB | ||
| 2025-04-28 10:17 | English | 3.6 KB | |||
| 2025-04-28 00:00 |
Hinweis auf Jahresfinanzbericht vom 01.01.2024 bis zum 31.12.2024
|
German | 6.1 KB | ||
| 2025-04-23 11:29 |
Epigenomics AG: Jahresergebnis zum 31. Dezember 2024 und Prognoseabweichung
|
German | 7.4 KB | ||
| 2025-01-22 15:05 |
Epigenomics AG: Vorlaufiges Jahresergebnis zum 31. Dezember 2024
|
German | 8.4 KB | ||
| 2025-01-21 15:05 |
Epigenomics AG: Vorlaufiges Jahresergebnis zum 31. Dezember 2024
|
German | 8.4 KB | ||
| 2024-07-30 00:00 |
Halbjahresfinanzbericht nach WpHG für den Zeitraum vom 01.01.2024 bis zum 30.06…
|
German | 116.7 KB | ||
| 2024-07-29 00:00 |
Hinweis auf Halbjahresfinanzbericht vom 01.01.2024 bis zum 30.06.2024
|
German | 5.8 KB | ||
| 2024-03-12 00:00 | German | 2.5 MB | |||
| 2024-03-06 00:00 |
Hinweis auf Jahresfinanzbericht vom 01.01.2023 bis zum 31.12.2023
|
German | 5.7 KB | ||
| 2023-08-10 00:00 |
Halbjahresfinanzbericht nach WpHG für den Zeitraum vom 01.01.2023 bis zum 30.06…
|
German | 161.3 KB | ||
| 2023-08-08 00:00 |
Hinweis auf Halbjahresfinanzbericht vom 01.01.2023 bis zum 30.06.2023
|
German | 5.7 KB | ||
| 2023-05-31 00:00 |
Q1 statement / Q1 financial report 2023
|
English | 674.3 KB | ||
| 2023-04-28 00:00 |
Annual financial report 2022
|
English | 1.6 MB | ||
| 2023-04-12 00:00 |
Hinweis auf Konzernabschluss vom 01.01.2022 bis zum 31.12.2022
|
German | 5.7 KB |
Automate Your Workflow. Get a real-time feed of all Epigenomics AG filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Epigenomics AG
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Epigenomics AG via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2022-12-27 | Ho, Dr. Selwyn | Board | Buy | None | 4,200.00 EUR |
| 2022-12-23 | von Prondzynski, Heino | Supervisory board | Buy | None | 5,625.00 EUR |
| 2022-12-22 | Ahlers, Felix | Board | Other | None | 22,000.00 EUR |
| 2022-12-22 | Lubenow, Dr. Helge | Supervisory board | Buy | None | 1,934.20 EUR |
| 2022-12-20 | von Prondzynski, Heino | Supervisory board | Buy | None | 3,680.00 EUR |
| 2022-12-16 | Lindenice GmbH | Board | Buy | None | 7,400.00 EUR |
| 2022-12-16 | Ho, Dr. Selwyn | Board | Buy | None | 6,780.00 EUR |
| 2022-12-14 | von Prondzynski, Heino | Supervisory board | Buy | None | 40,000.00 EUR |
Peer Companies
/other/DEFRAQ_Ventures_AG_formerly_VALE_MrJbW9G.webp)
